Concomitant medication

OTHER3 trials

Sponsors

GWT-TUD GmbH, Abteilung Medizin, Janssen Research & Development, LLC, Code Pharma

Conditions

D80.3HIVHIV InfectionLupus Erythematosus, Systemic

Phase 2

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

CompletedNCT02349061

Janssen Research & Development, LLCLupus Erythematosus, Systemic

Start: 2015-10-15End: 2019-03-13Updated: 2020-03-24

Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants

RecruitingNCT06676410

Code PharmaHIV, HIV Infection

Start: 2023-07-20End: 2024-12-31Target: 40Updated: 2024-11-06

Unknown Phase

Non-interventional study on the usage and outcomes of CUVITRU in patients with Primary Immunodeficiency Diseases

Active, not recruitingDRKS00014562

GWT-TUD GmbH, Abteilung MedizinD80.3

Start: 2018-11-27Target: 37Updated: 2025-04-07

Related Papers

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.

2023-09-266 citations

Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study

The Journal of Rheumatology2021-12-0127 citations

251 Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus

Abstracts2019-04-012 citations

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.

2018-09-21215 citations